专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明授权

US11684722B2 Drug delivery system with multipolar magnet and sensor system 有权
公开(公告)号：US11684722B2
公开(公告)日：2023-06-27
申请号：US16769643
申请日：2018-12-03
申请人： Novo Nordisk A/S
发明人： Laurits Hoejgaard Olesen , Henrik Bengtsson , Leif Johannsen , Keld Baden-Kristensen , John Aasted Soerensen
IPC分类号： A61M5/315 , A61M5/31
CPC分类号： A61M5/31553 , A61M5/3158 , A61M5/31525 , A61M5/31556 , A61M2005/3126 , A61M2205/3317 , A61M2205/52
摘要： A drug delivery system comprises an indicator element and a sensor system. The indicator element is arranged to rotate relative to a reference component and corresponding to a reference axis and comprises a plurality of dipole magnets. The sensor system comprises a plurality of magnetometers arranged non-rotational relative to the reference component and adapted to determine continuous magnetic field values from the plurality of dipole magnets, as well as processor means configured to determine on the basis of measured values from the plurality of magnetometers a rotational position and/or a rotational movement of the indicator element.

32. 发明公开

US20230158249A1 ACTIVATABLE DRUG DELVIERY DEVICE WITH SAFETY ASSEMBLY 审中-公开
公开(公告)号：US20230158249A1
公开(公告)日：2023-05-25
申请号：US17919110
申请日：2021-04-16
申请人： Novo Nordisk A/S
发明人： Willem Van Der Beek
IPC分类号： A61M5/315 , A61M5/32
CPC分类号： A61M5/31585 , A61M5/31595 , A61M5/31515 , A61M5/3202
摘要： A drug delivery device for delivering a dose of a medicament and a safety assembly for a drug delivery device, wherein the drug delivery device comprises a housing assembly, and a drive mechanism for delivering the dose, in response to activation. The drug delivery device further comprises an activation mechanism comprising a rotatable activation member (310), in response to an axial movement of the activation member, wherein the activation member (310) is adapted to be arranged in: (i) a first angular position, and (ii) a second angular position, wherein activation is allowed. The drug delivery device further comprises a ring member (390) as a part of a safety assembly. The ring member (390) is rotatable and axially splined to the activation member (310). Hereby, the ring member (390) is adapted to transfer a rotation to the activation member (310) from the first position to the second position, in response to a rotation of the ring member, whereby a user can rotate the activation member (310) without unintentionally activating the drive mechanism.

33. 发明授权

US11631486B2 Systems and methods for optimization of bolus timing relative to meal events 有权
公开(公告)号：US11631486B2
公开(公告)日：2023-04-18
申请号：US16323551
申请日：2017-08-14
申请人： Novo Nordisk A/S
发明人： Tinna Bjoerk Aradottir , Henrik Bengtsson , Pete Brockmeier , Jonas Kildegaard Pedersen
IPC分类号： G16H20/17 , G16H50/20 , G16H50/70 , G16H50/30 , G16H20/60 , A61K38/28 , A61M5/142 , G16H10/60 , A61B5/145 , A61M5/172
摘要： Systems and methods are provided for optimizing short acting insulin medicament dosage timing relative to a meal event for a subject. Glucose measurements of the subject over a time course and the timing of the measurements are obtained. Meal events in the time course and information regarding when dosages were injected into the subject relative to the meal events is obtained. Bins, each for a different time range for when a dosage is injected relative to a meal event, are constructed. Each bin is assigned glucose measurements in one or more periods within the time course in which the subject injected the dosage within the time range associated with the bin. A glycaemic risk measure is determined for each bin with the assigned measurements and used to identify an optimal relative time range for the subject. This is communicated to a health care practitioner or to the subject.

34. 发明授权

US11623049B2 Dose capturing assembly with secondary image analysis feature 有权
公开(公告)号：US11623049B2
公开(公告)日：2023-04-11
申请号：US16493658
申请日：2018-03-14
申请人： Novo Nordisk A/S
发明人： Bennie Peder Smiszek Pedersen
IPC分类号： A61M5/315 , A61M5/20 , A61M5/24 , G06F18/22 , A61M5/31 , G06V30/10
摘要： An add-on device for a drug delivery device comprises a camera for capturing an image of a scale drum, and a processor for determining the value of a captured image using a first image analysis process, the value corresponding to a set dose amount. If the determined value belongs to a pre-defined group of values, the determined value is confirmed using a second image analysis process in which for a given value from the pre-defined group of values one or more partial image areas and an associated nominal content thereof are pre-defined. If the captured content for each image area corresponds to the nominal content, the determined value is confirmed.

35. 发明申请

US20230050912A1 SELF-RIGHTING SYSTEMS AND RELATED COMPONENTS AND METHODS 有权
公开(公告)号：US20230050912A1
公开(公告)日：2023-02-16
申请号：US17826799
申请日：2022-05-27
申请人： Massachusetts Institute of Technology , The Brigham and Women's Hospital, Inc. , Novo Nordisk A/S
发明人： Carlo Giovanni Traverso , Alex G. Abramson , Ester Caffarel Salvador , Niclas Roxhed , Minsoo Khang , Taylor Bensel , Robert S. Langer , Jorrit Jeroen Water , Morten Revsgaard Frederiksen , Bo Uldall Kristiansen , Mikkel Oliver Jespersen , Mette Poulsen , Peter Herskind , Brian Jensen
IPC分类号： A61K9/48 , A61J3/07 , A61N1/36 , A61K9/00 , A61N1/32 , A61M5/32 , A61B5/145 , A61B10/02 , A61M5/20 , A61M31/00 , A61M5/142 , A61M5/158 , A61M37/00 , A61K38/28 , A61N1/05
摘要： Self-righting articles, such as self-righting capsules for administration to a subject, are generally provided. In some embodiments, the self-righting article may be configured such that the article may orient itself relative to a surface (e.g., a surface of a tissue of a subject). The self-righting articles described herein may comprise one or more tissue engaging surfaces configured to engage (e.g., interface with, inject into, anchor) with a surface (e.g., a surface of a tissue of a subject). In some embodiments, the self-righting article may have a particular shape and/or distribution of density (or mass) which, for example, enables the self-righting behavior of the article. In some embodiments, the self-righting article may comprise a tissue interfacing component and/or a pharmaceutical agent (e.g., for delivery of the active pharmaceutical agent to a location internal of the subject). In some cases, upon contact of the tissue with the tissue engaging surface of the article, the self-righting article may be configured to release one or more tissue interfacing components. In some cases, the tissue interfacing component is associated with a self-actuating component. For example, the self-righting article may comprise a self-actuating component configured, upon exposure to a fluid, to release the tissue interfacing component from the self-righting article. In some cases, the tissue interfacing component may comprise and/or be associated with the pharmaceutical agent (e.g., for delivery to a location internal to a subject).

36. 发明申请

US20230047780A1 FIXED DOSE INJECTION DEVICE 有权
公开(公告)号：US20230047780A1
公开(公告)日：2023-02-16
申请号：US17782313
申请日：2020-12-09
申请人： Novo Nordisk A/S
发明人： Bo Kvolsbjerg , Bjoern Gullak Larsen
IPC分类号： A61M5/315 , A61M5/20
摘要： A drug delivery device (100, 200) for delivering a fixed dose, comprising a drive mecha-nism comprising a drive spring (108, 208), and an activation mechanism comprising a connector (170, 270) adapted for activating the drive mechanism, wherein the drug de-livery device further comprises a split-dose-prevention mechanism adapted for limiting the axial movement of the connector during dosing. The split dose prevention mechanism comprises: (i) a split-dose-prevention structure (184, 284.1, 284.2) provided on the drive tube (180, 280) and extending in a circumferential direction, and (ii) a retention portion (178.3, 278.2) provided on the connector. For the drive tube being arranged in the intermediate position, the split-dose-prevention structure (184, 284.1, 284.2) and the retention portion are arranged with a transverse overlap, whereby movement of the connector in the second axial direction is limited by the split-dose prevention structure. For the drive tube being arranged in the stop position, the split-dose-prevention structure (184, 284.1, 284.2) and the retention portion are arranged with a transverse clearance and/or an axial gap, whereby the return spring (107, 207) can move the connector in the second axial direction, in response to releasing the applied force in the first direction on the connector.

37. 发明申请

US20230042451A1 COMPOSITIONS AND METHODS FOR INHIBITING MITOCHONDRIA AMIDOXIME REDUCING COMPONENT 1 (MARC1) EXPRESSION 有权
公开(公告)号：US20230042451A1
公开(公告)日：2023-02-09
申请号：US17826211
申请日：2022-05-27
申请人： Novo Nordisk A/S , Dicerna Pharmaceuticals, Inc.
发明人： Henryk Dudek , Wen Han , Natalie Wayne Pursell , Chengjung Lai , William Geoffrey Haynes , Zhihao Ding
IPC分类号： C12N15/113 , A61P1/16
摘要： Oligonucleotides are provided herein that inhibit MARC1 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with MARC1 expression.

38. 发明授权

US11572398B2 GLP-1 derivatives and uses thereof 有权
公开(公告)号：US11572398B2
公开(公告)日：2023-02-07
申请号：US15531105
申请日：2015-11-26
申请人： Novo Nordisk A/S
发明人： Per Sauerberg , Jacob Kofoed
IPC分类号： C07K14/605 , A61K47/54 , A61K47/59 , A61K38/00
摘要： The invention relates to a derivative of a GLP-1 analogue of a general Formula I, which derivative comprises a side chain attached to a Lys residue at position 34, 35, 36, 37, or 38 of the GLP-1 analogue, which side chain comprises a Branched linker, a 1st and a 2nd Protractor selected from C18 diacid, C20 diacid, and sulfonic acid C16, and at least one Linker element-1 incorporating ethylene glycol units. Linker element-1 may be incorporated in an optional Pre-linker, and/or in a 1st or 2nd Post-linker. The invention also relates to novel GLP-1 analogues, novel side chain intermediate products and their manufacture and use to prepare derivatives of biologically active peptides and proteins, as well as pharmaceutical compositions and medical uses of the analogues and derivatives. The derivatives have very long half-lives while maintaining a satisfactory potency, which makes them potentially suitable for once-monthly administration.

39. 发明申请

US20230000949A1 SOLID COMPOSITIONS COMPRISING A PCSK9 INHIBITOR AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID 有权
公开(公告)号：US20230000949A1
公开(公告)日：2023-01-05
申请号：US17773323
申请日：2020-11-06
申请人： Novo Nordisk A/S
发明人： Simon Bjerregaard , Ulrik Lytt Rahbek , Philip Jonas Sassene , Jorrit Jeroen Water , Andreas Vegge , Kaisa Naelapaeae
IPC分类号： A61K38/18 , A61K31/198 , A61K31/455 , A61K31/05 , A61K9/00 , A61K9/16
摘要： The invention relates to pharmaceutical compositions comprising a PCSK9 inhibitor, such as an EGF(A) peptide, and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.

40. 发明申请

US20220415465A1 SELF-BENCHMARKING FOR DOSE GUIDANCE ALGORITHMS 有权
公开(公告)号：US20220415465A1
公开(公告)日：2022-12-29
申请号：US17776146
申请日：2020-12-03
申请人： Novo Nordisk A/S
发明人： Henrik Bengtsson , Tinna Bjoerk Aradottir , Zeinab Mahmoudi , Ali Mohebbi , Julia Rosemary Thorpe
IPC分类号： G16H20/10 , G16H10/60 , A61B5/145 , A61B5/00
摘要： A benchmarking approach is employed that compares advice output from one or more alternative treatment guidance algorithms with a current actual treatment in terms of treatment outcomes. Treatment outcome for the current strategy is reflected in an actual BG outcome or profiled. Treatment outcome for an alternative algorithm-generated dose advice is based on a patient-specific model. The two sets of outcomes can be compared directly or using performance scores as a weighted combination that penalises or rewards certain outcomes. A statistical test may be applied to the accumulated results (paired outcomes or scores) to determine whether the algorithm is superior to the user's current dosing strategy, or alternative strategies.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式